Pear Therapeutics to offer its digital therapeutics through telehealth partners
The company's first telehealth offering is with PursueCare to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care.
Pear Therapeutics ended 2021 with $4.2M in revenue, expects $22M this year
Yes, the digital therapeutics market is taking off...
Study: Akili’s EndeavorRx digital therapeutic works
Data from the study show that EndeavorRx treatment resulted in increased brain activity related to attention function, as measured by EEG.
Pfizer, Alex Therapeutics team-up to provide evidence-based digital therapeutics starting with Germany
The partnership will utilize Alex Therapeutics' digital therapeutics platform, which combines evidence-based psychology, primarily CBT and ACT with AI.
Happify unveils the first digital therapeutics to treat both MDD and GAD
Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders.
Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal
The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
MindMaze scores new partners, enters new markets
Bringing the future of brain repair for stroke, Parkinson's, and other neurological conditions to patients in Latin America, Europe and Middle East.
Pear Therapeutics licenses multiple technologies to bolster its PDT platform
The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.
Pear Therapeutics launches Somryst for chronic insomnia
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
10 promising digital therapeutics
Today, we are witnessing an upsurge in health concerns. More than half of the population has diabetes, fluctuating blood pressure, and mental health issues....